SEC Comment Letter for Nautilus Biotechnology, Inc. (NAUT) (CIK 0001808805) (NAUT) — Aug 3, 2021
Nautilus Biotechnology, Inc. (NAUT) (CIK 0001808805)
Date: Aug. 3, 2021 · CIK: 0001808805 · Accession: 0000000000-21-009494
AI Filing Summary & Sentiment
File numbers found in text: 333-258100
Letter
United States securities and exchange commission logo August 3, 2021 Sujal Patel Chief Executive Officer Nautilus Biotechnology, Inc. 425 Pontius Ave N, Ste 202 Seattle, Washington 98109 Re:Nautilus Biotechnology, Inc. Registration Statement on Form S-1 Filed July 22, 2021 File No. 333-258100 Dear Mr. Patel: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Zachary B. Myers
Show Raw Text
United States securities and exchange commission logo
August 3, 2021
Sujal Patel
Chief Executive Officer
Nautilus Biotechnology, Inc.
425 Pontius Ave N, Ste 202
Seattle, Washington 98109
Re:Nautilus Biotechnology, Inc.
Registration Statement on Form S-1
Filed July 22, 2021
File No. 333-258100
Dear Mr. Patel:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Irene Paik at 202-551-6553 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Zachary B. Myers